...
首页> 外文期刊>Терапевтичесκий архив >Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome
【24h】

Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome

机译:骨髓增生异常综合征患者的形态学和细胞遗传学指标的预后潜力

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AIM: To examine prognostic potential of the number of bone marrow (BM) blasts and cell karyotype as risk factors of transformation of myelodysplastic syndrome (MDS) in acute myeloblastic leukemia AML. MATERIAL AND METHOD: The analysis of examination was made for 72 patients with primary MDS in the groups formed by number of blasts in BM, karyotype and IPSS variant. MDS was diagnosed by WHO criteria. Transformation into AML was established in blastosis > 20% in peripheral blood and/or BM. The karyotype was studied according to GTG technique. RESULTS: More frequent progression of MDS was seen in patients with blastosis > 10%, unfavourable karyotype and high IPSS risk. The least number of leukemic transformations occurred in karyotype of intermediate prognosis while disease-free survival in patients with karyotype of good prognosis was similar to that of patients with unfavourable karyotype. The number of blasts in BM and IPSS variant appeared to be prognostic markers of duration of leukemia-free survivalin one-factor analysis. The multifactorial analysis found out one factor of MDS transformation in AML: number of blasts in BM puncture biopsy. CONCLUSION: Prognostic priority of the number of BM blasts as a risk factor of MDS progression compared to karyotype is explained by biological heterogenicity of MDS.
机译:目的:探讨骨髓成骨细胞数和细胞核型的预后潜力,作为急性粒细胞白血病AML中转化为骨髓增生异常综合症(MDS)的危险因素。材料与方法:对72例原发性MDS患者进行了检查分析,这些患者是由BM,核型和IPSS变异的胚泡数目组成的。 MDS是根据WHO标准诊断的。外周血和/或BM中的胚芽增生> 20%时,已确立了向AML的转化。根据GTG技术研究核型。结果:blastosis> 10%,核型不良和IPSS风险高的患者中MDS的进展更为频繁。白血病转化最少的发生在中期预后的核型中,而预后良好的核型患者的无病生存与不良核型的患者相似。在单因素分析中,BM和IPSS变异中的胚细胞数目似乎是无白血病生存期的预后标志。多因素分析发现了AML中MDS转化的一个因素:BM穿刺活检中的胚泡数量。结论:MDS的生物学异质性解释了与核型相比,BM母细胞数目是MDS进展的危险因素的预后优先级。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号